AUTHOR=Han Guo-Dong , Sun Yuan , Hui Hong-Xia , Tao Ming-Yue , Liu Yang-Qing , Zhu Jing 

TITLE=MiR-1224 Acts as a Prognostic Biomarker and Inhibits the Progression of Gastric Cancer by Targeting SATB1

JOURNAL=Frontiers in Oncology

VOLUME=Volume 11 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.748896

DOI=10.3389/fonc.2021.748896

ISSN=2234-943X

ABSTRACT=Abstract. – OBJECTIVE: MiR-1224 has been reported to exhibit abnormal expression in several tumors, but the expressing pattern and roles of miR-1224 in gastric cancer (GC) remain unknown. Our current research was designed to delve into the potential involvement of miR-1224 in the GC progression. 
PATIENTS AND METHODS: The expression of miR-1224 was examined in tissue samples of 128 GC patients and cell lines by RT-PCR. The associations of miR-1224 expressions with clinicopathologic features and prognosis of GC patients were also analyzed. The possible influences of miR-1224 on cell proliferation and cell migration were determined. The molecular target of miR-1224 was identified using bioinformatics assays and confirmed experimentally. RT-PCR and Western blot assays were carried out for the exploration of the effect of abnormal miR-1224 expression on EMT and Wnt/β-catenin pathway.
RESULTS: miR-1224 was lowly expressed in the GC specimens and cell lines, and lower expressions of miR-1224 were correlated with T classification and TNM stage. Survival assays showed that GC patients with low expressions of miR-1224 had poor overall survivals. Moreover, in vitro and in vivo assays revealed that overexpression of miR-1224 inhibited cell proliferation, migration and invasion in GC cells. SATB1 was verified as a direct target of miR-1224 in GC. In addition, β-catenin and c-myc were significantly inhibited in miR-1224-overexpression cells.
CONCLUSIONS: Our findings highlight the potential of miR-1224 as a therapeutic target and novel biomarker for GC patients